Classification of Hodgkin lymphoma over years by Carbone, Antonino et al.
Leukaemia Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(10) 365 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
Classification of Hodgkin lymphoma over years 
Antonino Carbone, Annunziata Gloghini 
Department of Pathology Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale 
Tumori, IRCCS, Aviano, Italy; acarbone@cro.it (AC); Department of Diagnostic Pathology and 
Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 
annunziata.gloghini@istitutotumori.mi.it (AG) 
Published in Atlas Database: December 2016 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/ClassifHodgkinID1767.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68739/12-2016-ClassifHodgkinID1767.pdf 
DOI: 10.4267/2042/68739
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Histologic classification of Hodgkin lymphoma 
(HL) evolved through different systems, starting 
from the modern histologic classifications by 
Jackson and Parker in 1944 and Lukes and Butler in 
1966, to the 2008 World Health Organization 
(WHO) classification. HL has been classified into 
classical HL, which accounts for 95% of all HL 
cases, and the less common nodular lymphocyte 
predominant HL (NLPHL). Classical HL is a 
distinct neoplastic entity with typical clinical and 
epidemiological characteristics and unique 
pathological, genetic, and virological features. 
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Clinics and pathology 
Disease 
The modern classification scheme of Hodgkin 
lymphoma (HL) (Lukes, Craver, et al., 1966) is 
based on the concept that the histologic subtypes 
represent morphologic patterns of a neoplasm in 
which rare Hodgkin and Reed-Sternberg (HRS) 
cells, the HL tumor cells, are embedded in a 
dominant reactive background. Based on the 
morphologic characteristics of the HRS cells 
(lacunar cells, multinucleated giant cells, 
pseudosarcomatous cells) and the composition of 
the reactive infiltrate, four histologic subtypes have 
been distinguished: lymphocyte-rich cHL 
(LRCHL),nodular sclerosis (NS) cHL, mixed 
cellularity (MC) cHL, and lymphocyte depletion 
(LD) cHL. (Stein, 2001; Stein et al., 2008; 
Swerdlow et al., 2016). The background shows a 
cellular composition which is characteristic for each 
histotype. In MC cHL, microenvironmental cell 
types include T- and B-reactive lymphocytes, 
eosinophils, granulocytes, histiocytes/macrophages, 
plasma cells, mast cells. In addition, a great number 
of fibroblast-like cells and fibrosis are frequently 
found in NS cHL. 
Lymphocyte predominant (LP) HL, is characterized 
by a lymphocyte- rich background with admixed 
histiocytes. In 1944 Jackson and Parker called it in 
as "paragranuloma" to separate it from Hodgkin 
"granuloma". In 1966 Lukes and Butler (Lukes and 
Butler JJ, 1966) renamed paragranuloma 
"lymphocytic and/or histiocytic predominance HD", 
recognizing a nodular and a diffuse pattern and 
used the term of lymphocytic and histiocytic (L&H) 
RS-cell variant for the diagnostic cell (Lukes, 
Butler et al., 1966), now called LP cell. At the Rye 
symposium, it was decided to combine the nodular 
and diffuse types of the Lukes and Butler 
classification into LPHL (Lukes, Craver et al., 
1966) (Table 1). 
In the last decades, a considerable body of evidence 
has indicated that LPHL exhibits features of a B-
cell lymphoma, with a characteristic antigen profile 
and clinical behavior (reviewed in Younes et al., 
2014). This led the authors of the REAL 
classification proposal to separate LPHL as a 
distinct clinicopathologic entity from the other 
subtypes of HL, which were grouped under the 
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term "classical HL (CHL) ID: 1569> " (Harris et 
al.,1994; Mason et al., 1994; Stein, 2001; Stein et 
al., 2008) (Table 1). According to its cell of origin, 
phenotype and type of progression to large B-cell 
lymphoma, NLPHL should probably be considered 
as a B-cell lymphoma tout court. 
Phenotype/cell stem origin 
HL with a nodular growth pattern and a 
lymphocyte-rich background encompasses two 
entities, i.e. NLPHL and LRCHL with distinct 
phenotypical features. NLPHL which may contain a 
broad morphologic spectrum of neoplastic cells, 
exhibit a characteristic immunophenotype with 
expression of B-cell-specific antigens and absent 
expression of CD30 and CD15. 
LRCHL cases also exhibit, in the majority of cases, 
a nodular growth pattern as well as a broad 
morphologic spectrum of the neoplastic cells. The 
tumor cell phenotype, however, is always 
characteristic of CHL with expression of CD30 and 
CD15, infrequent expression of B-cell antigens 
(Figure 1). Furthermore, it could be shown by 
means of immunostains that the vast majority of 
LPHL cases contain areas with nodular growth 
pattern, whereas purely diffuse cases are extremely 
rare. Probably these cases, could be classified as 
grey zone lymphomas because they exhibit 
intermediate features between NLPHL and 
THCRLBCL (Figure 1) (Younes et al., 2014). 
Clinics 
Patients with LPHL and LRCHL usually differ 
from patients with NS cHL or MC cHL, as they 
presented with an earlier disease stage and 
infrequent mediastinal involvement. As most LPHL 
cases show a complete or partial nodular growth 
pattern, their differentiation from THCRLBCL is a 
rare problem (Table2). 
Pathology 
The question of the existence of diffuse LPHL 
became more complex when other authors 
described a diffuse large B-cell lymphoma variant, 
the so-called T-cell or histiocyte-rich large B-cell 
lymphoma (THCRLBCL), which frequently 
simulate the morphology of diffuse LPHL but 
exhibited an aggressive disease course (De Wolf-
Peeters et al., 2008; Carbone and Gloghini, 2016a). 
The cases identified as diffuse LPHL exhibit 
loosely distributed neoplastic cells embedded in a 
reactive background without evidence of nodularity 
.In these cases, which closely resemble 
THCRLBCL by conventional histology, a majority 
of the neoplastic cells have the morphologic 
features of LP cells. Immunophenotypic analysis 
can disclose an LP cell-characteristic phenotype 
with expression of CD20, CD79a, and EMA, 
whereas in-situ hybridization for EBER-transcripts 
does not provide evidence of a latent EBV 
infection. Due to the overlapping features between 
THRLBCL and LPHL, it is sometimes impossible 
to distinguish these two entities; thus, "grey zone" 
lymphoma is used to define some of those cases 
(De Wolf-Peeters et al., 2008; Younes et al., 2014) 
(Figure 1). 
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Also, nodular lymphocyte predominant Hodgkin 
lymphoma (NLPHL) and T-cell/histiocyte rich 
large B-cell lymphoma (THRLBCL) are closely 
related: both diseases contain neoplastic cells with 
similar morphologic and immunophenotypic 
features but differ with respect to their architecture 
and the nature of the reactive background (table 2). 
An additional type of HL with an abundance of 
lymphocytes was subsequently recognized. It was 
termed "lymphocyte-rich (LR) form of classical 
HL" and included in the REAL classification. This 
variant of classical HL (CHL), resembles, in terms 
of nodular growth and lymphocyte-richness, 
nodular LPHL and, in terms of the 
immunophenotype of the tumor cells, CHL (Figure 
1). Clinically, patients with LPHL and LRCHL 
show similar disease characteristics at presentation 
but differ in the frequency of multiple relapses and 
prognosis after relapse (Gloghini and Carbone, 
2016a; Gloghini and Carbone, 2016b). 
Other features 
In addition to immunophenotyping, in-situ 
hybridization for EBER detection can assist in the 
differential diagnosis between the two HL entities 
as the neoplastic cells in LPHD appear not to be 
permissive for an EBV infection (Table 3).  
EBV is found in HRS cells preferentially in cases 
of MC and LD cHL, and less frequently in NS and  
LRCHL. Notably, EBV is found in HRS cells in 
nearly all cases of cHL occurring in patients 
infected with HIV (Younes et al., 2014; Dolcetti et 
al., 2016; Carbone et al., 2016).  
The virologic characteristics of cHL vary according 
to the immunocompetence status of the host and 
cHL subtype (Carbone et al., 2016).  
Evolution 
NLPHL may evolve to a completely diffuse T-cell-
rich proliferation lacking any follicular dendritic 
cells which would be consistent with a THRLBCL 
or can be associated with such a proliferation at a 
separate site. 
NLPHL may evolve to a completely diffuse T-cell-
rich proliferation lacking any follicular dendritic 
cells which would be consistent with a THRLBCL 




See the pertinent sections within the CARDS of the 
Atlas of Genetics and Cytogenetics in Oncology 
and Haematology describing the general features of 
NLPHL and cHL (Küppers, 2011; Carbone and 
Gloghini, 2016b; Gloghini and Carbone, 2016a). 
 
 
    cHL  NLPHL THRLBCL 
Phenotype         
  CD15 + - - 
  CD20 Usually - + + 
  CD30 + - - or + 
  IRF4/MUM1 + + - or + 
  BCL6 + (30%) + - 
  EMA - + Usually - 
EBV infection         
    -/+* - - 
Background         
  T cells + - + 
  B cells / B and T cells + + - 
  CD57+ rosetting cells - + - 
  CD40L+ rosetting cells + + - 
  Histiocytes +/- +/- + 
  Eosinophils + - - 
  Plasma cells + - - 
  DRCs meshworks - /+ + - 
  Fibrosis + (Common) + (Rare) - 
Table 2. Phenotypic and virologic features of neoplastic cells of classic Hodgkin lymphoma (cHL), nodular lymphocyte 
predominance Hodgkin lymphoma (NLPHL) and T-cell/histiocyte rich large B-cell lymphoma (THRLBCL) *Association with EBV 
is less frequent in NS than in MC cHL and LRCHL. 
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Host Hodgkin lymphoma subtype EBV infection 
HL of the general population 
  
 
Nodular lymphocyte predominance - 
 
cHL, nodular sclerosis Usually -* 
 





cHL, lymphocyte rich Variably + 
 






cHL, lymphocyte depleted + 
 





cHL, lymphohistiocyoid + 
 
cHL, nodular sclerosis + 
Table 3. Morphologic and virologic characteristics of Hodgkin lymphoma. Abbreviations. cHL, classical Hodgkin lymphoma; 
-, negative; +, positive. *Association with EBV is less frequent in ns (10-40%) than in mc cHL (approximately 75% of cases) 
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